Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.25.1 (
proteasome
)
28,817
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Skeletal muscles contain heterogeneous myofibers that are different in size and contractile speed, with type IIb myofiber being the largest and fastest. Here, we identify methyltransferase-like 21e (Mettl21e), a member of newly classified nonhistone methyltransferases, as a gene enriched in type IIb myofibers. The expression of
Mettl21e
was strikingly up-regulated in hypertrophic muscles and during myogenic differentiation
in vitro
and
in vivo
. Knockdown (KD) of
Mettl21e
led to atrophy of cultured myotubes, and targeted mutation of
Mettl21e
in mice reduced the size of IIb myofibers without affecting the composition of myofiber types. Mass spectrometry and methyltransferase assay revealed that Mettl21e methylated valosin-containing protein (Vcp/p97), a key component of the ubiquitin-
proteasome
system. KD or knockout of Mettl21e resulted in elevated 26S
proteasome
activity, and inhibition of
proteasome
activity prevented atrophy of
Mettl21e
KD myotubes. These results demonstrate that Mettl21e functions to maintain myofiber size through inhibiting
proteasome
-mediated protein degradation.-Wang, C., Zhang, B., Ratliff, A. C., Arrington, J., Chen, J., Xiong, Y., Yue, F., Nie, Y., Hu, K., Jin, W.,
Tao
, W. A., Hrycyna, C. A., Sun, X., Kuang, S. Methyltransferase-like 21e inhibits 26S
proteasome
activity to facilitate hypertrophy of type IIb myofibers.
...
PMID:Methyltransferase-like 21e inhibits 26S proteasome activity to facilitate hypertrophy of type IIb myofibers. 3116 44